View Financial HealthInfant Bacterial Therapeutics 配当と自社株買い配当金 基準チェック /06Infant Bacterial Therapeutics配当金を支払った記録がありません。主要情報n/a配当利回りn/aバイバック利回り総株主利回りn/a将来の配当利回りn/a配当成長n/a次回配当支払日n/a配当落ち日n/a一株当たり配当金n/a配当性向n/a最近の配当と自社株買いの更新更新なしすべての更新を表示Recent updatesお知らせ • Mar 31Infant Bacterial Therapeutics AB (publ), Annual General Meeting, May 07, 2026Infant Bacterial Therapeutics AB (publ), Annual General Meeting, May 07, 2026, at 16:00 W. Europe Standard Time. Location: convendum, fleminggatan 18, stockholm Swedenお知らせ • Feb 06+ 2 more updatesInfant Bacterial Therapeutics AB (publ) to Report Fiscal Year 2025 Final Results on Mar 27, 2026Infant Bacterial Therapeutics AB (publ) announced that they will report fiscal year 2025 final results at 7:30 AM, Central European Standard Time on Mar 27, 2026お知らせ • Nov 13+ 1 more updateInfant Bacterial Therapeutics AB (publ) to Report First Half, 2026 Results on Aug 25, 2026Infant Bacterial Therapeutics AB (publ) announced that they will report first half, 2026 results on Aug 25, 2026お知らせ • May 07Infant Bacterial Therapeutics AB (publ) to Report Fiscal Year 2025 Results on Feb 06, 2026Infant Bacterial Therapeutics AB (publ) announced that they will report fiscal year 2025 results at 8:00 AM, Central European Standard Time on Feb 06, 2026お知らせ • Apr 24Infant Bacterial Therapeutics to Present Results of the Connection Study at Las 2025 in HawaiiInfant Bacterial Therapeutics (IBT) announced that results from its pivotal Phase III trial, "The Connection Study," will be presented at the Pediatric Academic Societies (PAS) 2025 Annual Meeting in Honolulu, Hawaii, on April 26, 2025. Both the oral and poster presentations will take place at the Hawaii Convention Center and will be delivered by Prof. Josef Neu, Principal Investigator of the study and Professor of Pediatrics at the University of Florida. The PAS 2025 Meeting, held from is a premier international forum for pediatric April 24-28, researchers, clinicians, and educators. IBT's presentations will spotlight findings from its investigational therapeutic IBP-9414, a live biotherapeutic product designed to prevent necrotizing enterocolitis (NEC) and reduce all-cause mortality in preterm infants.お知らせ • Apr 08Infant Bacterial Therapeutics AB (publ), Annual General Meeting, May 08, 2025Infant Bacterial Therapeutics AB (publ), Annual General Meeting, May 08, 2025, at 16:00 W. Europe Standard Time. Location: at wetmanska palatset, conference room, bryggarkungen, hollandargatan 17, stockholm Swedenお知らせ • Nov 14+ 2 more updatesInfant Bacterial Therapeutics AB (publ) to Report Q3, 2025 Results on Nov 13, 2025Infant Bacterial Therapeutics AB (publ) announced that they will report Q3, 2025 results at 8:30 AM, Central European Standard Time on Nov 13, 2025お知らせ • Oct 09Infant Bacterial Therapeutics AB (Publ) Announces the Appointment of the Nomination Committee for the Annual General Meeting 2025Infant Bacterial Therapeutics AB (publ) announced that the Nomination Committee for the Annual General Meeting 2025 has been formed in accordance with the decision of the Annual General Meeting. The Nomination Committee consists of David Dangoor (Chairman of the Nomination Committee), appointed by the largest shareholder Annwall & Rothschild Investments AB, Sebastian Jahreskog, who through direct and indirect ownership is the company's second largest shareholder, and Jannis Kitsakis, appointed by the third largest shareholder, Fjärde AP-fonden. In addition, Peter Rothschild is a member of the Nomination Committee in his capacity as Chairman of the Board.お知らせ • Aug 31Infant Bacterial Therapeutics Announces Results of Phase III Study Shows No Significant Effects on the Primary EndpointsInfant Bacterial Therapeutics has conducted a phase III study comprising 2153 premature infants for five years. The objective of the study has been to show that the company's drug candidate IBP-9414, a bacterial strain found naturally in human breast milk, can improve the health of premature infants by preventing necrotizing enterocolitis (NEC) and improve premature infants' gastrointestinal function (measured as time to Sustained Feeding Tolerance, SFT) and, as a secondary objective, reduce death. The results of the study have now been analyzed according to the pre-specified statistical analysis plan. Although these analysis showed positive trends, there were no statistical significance for the two primary endpoints: prevention of necrotizing enterocolitis (NEC), active group: 8.7% vs placebo group: 10.2% (p=0.24) and SFT, active group: 16 days vs placebo group: 17 days (p=0.07). Importantly, there was a significant reduction in the secondary endpoint of all-cause mortality, active group: 6.2% vs placebo group: 8.5% (p=0.04), corresponding to a significant risk reduction of 27%, which meant that in reality 23 infants' lives were spared by the administration of IBP-9414 in the study. IBT will continue the development towards pharmaceutical registration, considering that the study showed statistical significance on all-cause mortality. The previous communicated timeline for the registration might be affected and IBT will revert with an update if any changes will occur. The risk reduction of 27% in mortality is a substantial effect size and comparable to currently available pharmaceutical products, for example, surfactants used in the neonatal intensive care units. The effect of IBP-9414 could potentially save the lives of thousands of infants per year and is the only Live Biopharmaceutical candidate that has shown a strong advantage in saving premature infants' lives. Furthermore the study shows that giving IBP-9414 to these very vulnerable premature infants does not cause any safety issues, including the risk of sepsis which has been a concern expressed by the FDA for the use of probiotic products in preterm infants.お知らせ • Mar 26+ 1 more updateInfant Bacterial Therapeutics AB (publ) to Report Nine Months, 2024 Results on Nov 14, 2024Infant Bacterial Therapeutics AB (publ) announced that they will report nine months, 2024 results on Nov 14, 2024お知らせ • Aug 26Infant Bacterial Therapeutics AB (publ), Annual General Meeting, May 08, 2024Infant Bacterial Therapeutics AB (publ), Annual General Meeting, May 08, 2024, at 16:00 Central European Standard Time.決済の安定と成長配当データの取得安定した配当: IFTB.Fの 1 株当たり配当が過去に安定していたかどうかを判断するにはデータが不十分です。増加する配当: IFTB.Fの配当金が増加しているかどうかを判断するにはデータが不十分です。配当利回り対市場Infant Bacterial Therapeutics 配当利回り対市場IFTB.F 配当利回りは市場と比べてどうか？セグメント配当利回り会社 (IFTB.F)n/a市場下位25% (US)1.4%市場トップ25% (US)4.2%業界平均 (Pharmaceuticals)2.1%アナリスト予想 (IFTB.F) (最長3年)n/a注目すべき配当: IFTB.Fは最近配当金を報告していないため、配当金支払者の下位 25% に対して同社の配当利回りを評価することはできません。高配当: IFTB.Fは最近配当金を報告していないため、配当金支払者の上位 25% に対して同社の配当利回りを評価することはできません。株主への利益配当収益カバレッジ: IFTB.Fの 配当性向 を計算して配当金の支払いが利益で賄われているかどうかを判断するにはデータが不十分です。株主配当金キャッシュフローカバレッジ: IFTB.Fが配当金を報告していないため、配当金の持続可能性を計算できません。高配当企業の発掘7D1Y7D1Y7D1YUS 市場の強力な配当支払い企業。View Management企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/19 08:36終値2026/02/19 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Infant Bacterial Therapeutics AB (publ) 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
お知らせ • Mar 31Infant Bacterial Therapeutics AB (publ), Annual General Meeting, May 07, 2026Infant Bacterial Therapeutics AB (publ), Annual General Meeting, May 07, 2026, at 16:00 W. Europe Standard Time. Location: convendum, fleminggatan 18, stockholm Sweden
お知らせ • Feb 06+ 2 more updatesInfant Bacterial Therapeutics AB (publ) to Report Fiscal Year 2025 Final Results on Mar 27, 2026Infant Bacterial Therapeutics AB (publ) announced that they will report fiscal year 2025 final results at 7:30 AM, Central European Standard Time on Mar 27, 2026
お知らせ • Nov 13+ 1 more updateInfant Bacterial Therapeutics AB (publ) to Report First Half, 2026 Results on Aug 25, 2026Infant Bacterial Therapeutics AB (publ) announced that they will report first half, 2026 results on Aug 25, 2026
お知らせ • May 07Infant Bacterial Therapeutics AB (publ) to Report Fiscal Year 2025 Results on Feb 06, 2026Infant Bacterial Therapeutics AB (publ) announced that they will report fiscal year 2025 results at 8:00 AM, Central European Standard Time on Feb 06, 2026
お知らせ • Apr 24Infant Bacterial Therapeutics to Present Results of the Connection Study at Las 2025 in HawaiiInfant Bacterial Therapeutics (IBT) announced that results from its pivotal Phase III trial, "The Connection Study," will be presented at the Pediatric Academic Societies (PAS) 2025 Annual Meeting in Honolulu, Hawaii, on April 26, 2025. Both the oral and poster presentations will take place at the Hawaii Convention Center and will be delivered by Prof. Josef Neu, Principal Investigator of the study and Professor of Pediatrics at the University of Florida. The PAS 2025 Meeting, held from is a premier international forum for pediatric April 24-28, researchers, clinicians, and educators. IBT's presentations will spotlight findings from its investigational therapeutic IBP-9414, a live biotherapeutic product designed to prevent necrotizing enterocolitis (NEC) and reduce all-cause mortality in preterm infants.
お知らせ • Apr 08Infant Bacterial Therapeutics AB (publ), Annual General Meeting, May 08, 2025Infant Bacterial Therapeutics AB (publ), Annual General Meeting, May 08, 2025, at 16:00 W. Europe Standard Time. Location: at wetmanska palatset, conference room, bryggarkungen, hollandargatan 17, stockholm Sweden
お知らせ • Nov 14+ 2 more updatesInfant Bacterial Therapeutics AB (publ) to Report Q3, 2025 Results on Nov 13, 2025Infant Bacterial Therapeutics AB (publ) announced that they will report Q3, 2025 results at 8:30 AM, Central European Standard Time on Nov 13, 2025
お知らせ • Oct 09Infant Bacterial Therapeutics AB (Publ) Announces the Appointment of the Nomination Committee for the Annual General Meeting 2025Infant Bacterial Therapeutics AB (publ) announced that the Nomination Committee for the Annual General Meeting 2025 has been formed in accordance with the decision of the Annual General Meeting. The Nomination Committee consists of David Dangoor (Chairman of the Nomination Committee), appointed by the largest shareholder Annwall & Rothschild Investments AB, Sebastian Jahreskog, who through direct and indirect ownership is the company's second largest shareholder, and Jannis Kitsakis, appointed by the third largest shareholder, Fjärde AP-fonden. In addition, Peter Rothschild is a member of the Nomination Committee in his capacity as Chairman of the Board.
お知らせ • Aug 31Infant Bacterial Therapeutics Announces Results of Phase III Study Shows No Significant Effects on the Primary EndpointsInfant Bacterial Therapeutics has conducted a phase III study comprising 2153 premature infants for five years. The objective of the study has been to show that the company's drug candidate IBP-9414, a bacterial strain found naturally in human breast milk, can improve the health of premature infants by preventing necrotizing enterocolitis (NEC) and improve premature infants' gastrointestinal function (measured as time to Sustained Feeding Tolerance, SFT) and, as a secondary objective, reduce death. The results of the study have now been analyzed according to the pre-specified statistical analysis plan. Although these analysis showed positive trends, there were no statistical significance for the two primary endpoints: prevention of necrotizing enterocolitis (NEC), active group: 8.7% vs placebo group: 10.2% (p=0.24) and SFT, active group: 16 days vs placebo group: 17 days (p=0.07). Importantly, there was a significant reduction in the secondary endpoint of all-cause mortality, active group: 6.2% vs placebo group: 8.5% (p=0.04), corresponding to a significant risk reduction of 27%, which meant that in reality 23 infants' lives were spared by the administration of IBP-9414 in the study. IBT will continue the development towards pharmaceutical registration, considering that the study showed statistical significance on all-cause mortality. The previous communicated timeline for the registration might be affected and IBT will revert with an update if any changes will occur. The risk reduction of 27% in mortality is a substantial effect size and comparable to currently available pharmaceutical products, for example, surfactants used in the neonatal intensive care units. The effect of IBP-9414 could potentially save the lives of thousands of infants per year and is the only Live Biopharmaceutical candidate that has shown a strong advantage in saving premature infants' lives. Furthermore the study shows that giving IBP-9414 to these very vulnerable premature infants does not cause any safety issues, including the risk of sepsis which has been a concern expressed by the FDA for the use of probiotic products in preterm infants.
お知らせ • Mar 26+ 1 more updateInfant Bacterial Therapeutics AB (publ) to Report Nine Months, 2024 Results on Nov 14, 2024Infant Bacterial Therapeutics AB (publ) announced that they will report nine months, 2024 results on Nov 14, 2024
お知らせ • Aug 26Infant Bacterial Therapeutics AB (publ), Annual General Meeting, May 08, 2024Infant Bacterial Therapeutics AB (publ), Annual General Meeting, May 08, 2024, at 16:00 Central European Standard Time.